Investing.com - Vir Biotech reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Vir Biotech announced earnings per share of $1.30 on revenue of $374.6M. Analysts polled by Investing.com anticipated EPS of $-0.42 on revenue of $146.35M.
Vir Biotech shares are up 18% from the beginning of the year and are trading at $23.18 , down-from-52-week-high.
Vir Biotech shares gained 6.33% in after-hours trade the report.
Vir Biotech follows other major Healthcare sector earnings this month
Vir Biotech's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.9B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar